This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Tuberculosis/ Other Mycobacterium  • Pulmonary Diseases, Other  • Drug Therapy, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:2705-2707.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

As the current standard of care for tuberculosis (TB) is based on less-than-ideal drugs that were discovered over four decades ago, TB treatment could use a shot in the arm. And indeed, renewed interest in TB drug research across the board in the nonprofit, academic, and commercial realms is funneling promising candidates into the TB drug pipeline.

"A number of years ago, there was nothing on the horizon, and now everyone’s energized," said Scott Franzblau, PhD, director of the Institute for Tuberculosis Research at the University of Illinois at Chicago.

By the end of this year, at least a half dozen drugs will be in clinical trials for TB, said Melvin Spigelman, MD, director of research and development at the nonprofit Global Alliance for TB Drug Development (the TB Alliance), in New York City. "I don’t think anyone would’ve predicted that."

Researchers force tuberculosis (TB) bacteria into . . . [Full Text of this Article]

DRUGS ON THE HORIZON